CMN-001

N/A

Report date: 2023/10/03 20:06:05

Base Information

Drug NameCMN-001

Drug Alias NameAutologous Dendritic Cell Therapy (CoImmune)CMN-001

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCoimmune

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCoimmune

Active IndicationsN/A

Inactive IndicationsCarcinoma, Renal Cell

Other Information

ATC CodeN/A